The pathogenesis of prostate cancer: from molecular to metabolic alterations

Diagnostic Histopathology

Volumn 14, Issue 5, 2008, Pages 195-201

  Benedettini, Elisa ^a,b   Nguyen, Paul ^a,b   Loda, Massimo ^a,b  

^a Harvard Medical School ^*

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

FASN; genetic mutations; lipid metabolism; prostate cancer; risk stratification; therapeutic approaches

Indexed keywords

FATTY ACID SYNTHASE;

ANAEROBIC GLYCOLYSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RISK; CELL GROWTH; CELL SURVIVAL; GENE IDENTIFICATION; GENE MUTATION; GENOME; HEREDITY; HUMAN; LIPID METABOLISM; LIPOGENESIS; MALE; PATHOGENESIS; PROSTATE CANCER; RISK ASSESSMENT;

EID: 44949244988     PISSN: 17562317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mpdhp.2008.03.001     Document Type: Article

References (50)

1. Walczak J.R., and Carducci M.A. Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 82 (2007) 243-249
2. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
3. Wright M.E., Chang S.C., Schatzkin A., et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer (2007)
4. Loeb S., and Catalona W.J. Prostate-specific antigen in clinical practice. Cancer Lett 249 (2007) 30-39
5. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
6. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
7. Cooperberg M.R., Lubeck D.P., Meng M.V., Mehta S.S., and Carroll P.R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22 (2004) 2141-2149
8. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
9. Bostwick D.G., Shan A., Qian J., et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 83 (1998) 1995-2002
10. DeMarzo A.M., Nelson W.G., Isaacs W.B., and Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 361 (2003) 955-964
11. Freedman M.L., Haiman C.A., Patterson N., et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Nat Acad Sci USA 103 (2006) 14068-14073
12. Amundadottir L.T., Sulem P., Gudmundsson J., et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 38 (2006) 652-658
13. Peehl D.M. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 12 (2005) 19-47
14. Bradford T.J., Tomlins S.A., Wang X., and Chinnaiyan A.M. Molecular markers of prostate cancer. Urol Oncol 24 (2006) 538-551
15. Yu Y.P., Landsittel D., Jing L., et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22 (2004) 2790-2799
16. Roy-Burman P., Wu H., Powell W.C., Hagenkord J., and Cohen M.B. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 11 (2004) 225-254
17. Majumder P.K., Yeh J.J., George D.J., et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Nat Acad Sci USA 100 (2003) 7841-7846
18. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
19. Wang J., Cai Y., Ren C., and Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 66 (2006) 8347-8351
20. Li L.C., Carroll P.R., and Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97 (2005) 103-115
21. De Marzo A.M., DeWeese T.L., Platz E.A., et al. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J Cell Biochem 91 (2004) 459-477
22. Henrique R., and Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 46 (2004) 660-669 (discussion: 669)
23. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
24. Costello L.C., and Franklin R.B. 'Why do tumour cells glycolyse?': from glycolysis through citrate to lipogenesis. Mol Cell Biochem 280 (2005) 1-8
25. Kuhajda F.P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16 (2000) 202-208
26. Menendez J.A., and Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7 (2007) 763-777
27. Kuhajda F.P., Pizer E.S., Li J.N., Mani N.S., Frehywot G.L., and Townsend C.A. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Nat Acad Sci USA 97 (2000) 3450-3454
28. Rossi S., Graner E., Febbo P., et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1 (2003) 707-715
29. Baron A., Migita T., Tang D., and Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J Cell Biochem 91 (2004) 47-53
30. Pizer E.S., Pflug B.R., Bova G.S., Han W.F., Udan M.S., and Nelson J.B. Increased fatty acid synthase as a therapeutic target in androgen- independent prostate cancer progression. Prostate 47 (2001) 102-110
31. Pflug B.R., Pecher S.M., Brink A.W., Nelson J.B., and Foster B.A. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate 57 (2003) 245-254
32. Little J.L., Wheeler F.B., Fels D.R., Koumenis C., and Kridel S.J. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 67 (2007) 1262-1269
33. Swinnen J.V., Van Veldhoven P.P., Timmermans L., et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 302 (2003) 898-903
34. Freeman M.R., and Solomon K.R. Cholesterol and prostate cancer. J Cell Biochem 91 (2004) 54-69
35. Yang G., Truong L.D., Wheeler T.M., and Thompson T.C. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59 (1999) 5719-5723
36. Williams T.M., Hassan G.S., Li J., et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 280 (2005) 25134-25145
37. Di Vizio D., Sotgia F., Williams T.M., et al. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther 6 (2007) 1263-1268
38. Zhuang L., Lin J., Lu M.L., Solomon K.R., and Freeman M.R. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 62 (2002) 2227-2231
39. Kridel S.J., Axelrod F., Rozenkrantz N., and Smith J.W. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64 (2004) 2070-2075
40. Kato K., Der C.J., and Buss J.E. Prenoids and palmitate: lipids that control the biological activity of Ras proteins. Semin Cancer Biol 3 (1992) 179-188
41. Hochachka P.W., Rupert J.L., Goldenberg L., Gleave M., and Kozlowski P. Going malignant: the hypoxia-cancer connection in the prostate. Bioessays 24 (2002) 749-757
42. Myers R.B., Oelschlager D.K., Weiss H.L., Frost A.R., and Grizzle W.E. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol 165 (2001) 1027-1032
43. Rossi S., Graner E., Febbo P., et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1 (2003) 707-715
44. Priolo C., Tang D., Brahamandan M., et al. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 66 (2006) 8625-8632
45. Graner E., Tang D., Rossi S., et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5 (2004) 253-261
46. Ruderman N., and Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3 (2004) 340-351
47. Laukkanen J.A., Laaksonen D.E., Niskanen L., Pukkala E., Hakkarainen A., and Salonen J.T. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13 (2004) 1646-1650
48. Chakravarty B., Gu Z., Chirala S.S., Wakil S.J., and Quiocho F.A. Human fatty acid synthase: structure and substrate selectivity of the thioesterase domain. P. Proc Nat Acad Sci USA 101 (2004) 15567-15572
49. Renatus M., Parrado S.G., D'Arcy A., et al. Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 14 (2006) 1293-1302
50. Townley R., and Shapiro L. Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. Science 315 (2007) 1726-1729